A Phase I Clinical Study of the Pharmacokinetics and Safety of Technetium [99mTc]-H7ND Injection in Patients With Gastrointestinal Malignancies and Healthy Volunteers
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Technetium [99mTc] H7ND (Primary)
- Indications Gastrointestinal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors PharmaDax
Most Recent Events
- 20 Sep 2024 Status changed from not yet recruiting to recruiting.
- 11 Jun 2024 New trial record